Research and Development

Group Hopes to Turn Around Failed Lung Cancer Drugs

A UK coalition of drugmakers and a cancer research group are launching an analysis of failed Phase III lung cancer drug trials that will search for treatments that, despite failing overall, are effective for certain subpopulations. Read More